2025年10月30日,康方生物宣布,公司全球首创双特异性抗体新药依沃西(PD-1/VEGF双抗)联合化疗,治疗EGFR-TKI治疗进展的EGFR突变非鳞状非小细胞肺癌(nsq-NSCLC)患者的III期HARMONi-A研究的最终总生存期(OS)分析显著性结果,已入选2025年11月7–9日在美国马里兰州国家海港举办的美国免疫治疗学会(SITC)第40届年会“最新突破性摘要”(LBA),将在大会...
Source Link2025年10月30日,康方生物宣布,公司全球首创双特异性抗体新药依沃西(PD-1/VEGF双抗)联合化疗,治疗EGFR-TKI治疗进展的EGFR突变非鳞状非小细胞肺癌(nsq-NSCLC)患者的III期HARMONi-A研究的最终总生存期(OS)分析显著性结果,已入选2025年11月7–9日在美国马里兰州国家海港举办的美国免疫治疗学会(SITC)第40届年会“最新突破性摘要”(LBA),将在大会...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.